Serva Energy was featured recently in a new podcast from Drug Discovery News  (DDN) highlighting the history of Actinium-225 and its potential as a promising cancer treatment. Stephanie DeMarco, PhD, the host of DDN Dialogues, takes listeners on a journey deep into the core of what makes Actinium-225 the Goldilocks of radioisotopes when it comes to killing cancer cells and why Serva is poised to significantly scale production of this exceedingly rare and valuable isotope. DDN

Serva Energy’s collaboration with the University of California—Irvine Nuclear Reactor Facility was highlighted in a recent news story (March 25, 2024 ) about how the facility is helping usher in a new generation of nuclear scientists. Having famously helped analyze the bullets that killed President John F. Kennedy, the UCI facility, with the support of UCI Assistant Professor Sarah Finkeldei, is collaborating with nuclear innovators, such as Serva, on promising solutions and

NEWS RELEASE November 1, 2023 Serva Energy’s sample measurement of the rare, cancer-killing medical isotope Actinium-225 has been validated by the Massachusetts Institute of Technology (MIT) Nuclear Research Laboratory. It’s the latest milestone in Serva’s development of commercial quantities of Actinium-225 (Ac-225) needed for next-generation Targeted Alpha Therapies. “Some of the best scientists in the world have demonstrated the power of our technology,” said Ian Horva

Nuclear innovation was the focus of a Nuclear Science Week national expo event, Saturday, Oct. 14, with the University of California—Irvine. Members of the Serva team came together with more than 1,200 people—students, educators, and community members—for a day of learning and fun around nuclear science and innovation. “It’s always great talking with kids and members of the community about all the awesome things happening right now in nuclear,” said Ian Horvath, founder and C